A versatile in vivo chamber angiogenesis assay for measuring anti-angiogenic activity in mice

Oncology Reports

Volumn 11, Issue 2, 2004, Pages 303-307

  Kragh, Michael ^a   Hjarnaa, Pernille Julia V ^a   Bramm, Erik ^a   Binderup, Lise ^a  

^a LEO PHARMA A S   (Denmark)

Author keywords

Angiogenesis; bFGF; Chamber; Matrigel; Mice; TNP 470

Indexed keywords

ANGIOGENESIS INHIBITOR; FIBROBLAST GROWTH FACTOR 2;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; FEMALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; FEMALE; FIBROBLAST GROWTH FACTOR 2; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC;

EID: 3242752152     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.2.303     Document Type: Article

References (20)

1. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003. (Pubitemid 37328844)
2. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL and Hennequin LF: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655, 2002.
3. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS and Park JW: YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95: 516-525, 2003. (Pubitemid 36511622)
4. Dupont E, Falardeau P, Mousa SA, Dimitriadou V, Pepin MC, Wang T and Alaoui-Jamali MA: Antiangiogenic and anti-metastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 19: 145-153, 2002. (Pubitemid 34264084)
5. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G and Hallahan DE: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63: 4009-4016, 2003. (Pubitemid 36917920)
6. Scappaticci FA: The therapeutic potential of novel antiangiogenic therapies. Expert Opin Investig Drugs 12: 923-932, 2003.
7. Madhusudan S and Harris AL: Drug inhibition of angiogenesis. Curr Opin Pharmacol 2: 403-414, 2002. (Pubitemid 34830971)
8. Jain RK, Schlenger K, Hockel M and Yuan F: Quantitative angiogenesis assays: progress and problems. Nat Med 3: 1203-1208, 1997. (Pubitemid 27508819)
9. Auerbach R, Lewis R, Shinners B, Kubai L and Akhtar N: Angiogenesis assays: a critical overview. Clin Chem 49: 32-40, 2003. (Pubitemid 36078551)
10. Shin SH, Kim JC, Chang SI, Lee H and Chung SI: Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin. Cornea 19: 212-217, 2000. (Pubitemid 30140826)
11. Monsky WL, Mouta Carreira C, Tsuzuki Y, Gohongi T, Fukumura D and Jain RK: Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 8: 1008-1013, 2002. (Pubitemid 35177349)
12. Pahernik S, Harris AG, Schmitt-Sody M, Krasnici S, Goetz AE, Dellian M and Messmer K: Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study. Br J Cancer 86: 1622-1627, 2002. (Pubitemid 34628117)
13. Norrby K: Constitutively synthesized nitric oxide is a physiological negative regulator of mammalian angiogenesis mediated by basic fibroblast growth factor. Int J Exp Pathol 81: 423-427, 2000
14. Merchan JR, Chan B, Kale S, Schnipper LE and Sukhatme VP: In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst 95: 388-399, 2003. (Pubitemid 36395259)
15. Kragh M, Hjarnaa PJ, Bramm E, Kristjansen PE, Rygaard J and Binderup L: In vivo chamber angiogenesis assay: an optimized Matrigel plug assay for fast assessment of anti-angiogenic activity. Int J Oncol 22: 305-311, 2003.
16. Ruggeri BA, Robinson C, Angeles T, Wilkinson J IV and Clapper ML: The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin Cancer Res 8: 267-274 2002. (Pubitemid 34101487)
17. Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM and Stetler-Stevenson WG: Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 162: 1431-1439, 2003. (Pubitemid 36512825)
18. Akhtar N, Dickerson EB and Auerbach R: The sponge/Matrigel angiogenesis assay. Angiogenesis 5: 75-80, 2002. (Pubitemid 36076925)
19. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J and Klagsbrun M: Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 223: 1296-1299, 1984. (Pubitemid 14163183)
20. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H and Folkman J: Synthetic analogs of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557, 1990. (Pubitemid 120015110)